Recovery of horses from general anesthesia in a darkened or illuminated recovery stall

ObjectiveTo assess whether recovery from general anesthesia, in an illuminated or a darkened stall, has an effect on time to first movement, time to standing, and recovery score.Study designProspective randomized clinical study.AnimalsTwenty-nine healthy, 2- to 5-year-old horses undergoing surgical correction of dorsal displacement of the soft palate.MethodsEach horse was assigned randomly to recover in either an illuminated (n = 15) or a darkened stall (n = 14). For pre-anesthetic medication, all horses received intravenous (IV) xylazine (0.4 mg kg⁻¹) and butorphanol (0.02 mg kg⁻¹). Anesthesia was induced with midazolam (0.1 mg kg⁻¹) and ketamine (2.2 mg kg⁻¹) IV and maintained on isoflurane in oxygen. Vital parameters, end-tidal CO₂ and isoflurane were recorded at 5-minute intervals. At the conclusion of anesthesia, horses were placed in either an illuminated or a darkened stall and xylazine (0.2 mg kg⁻¹) IV was administered at extubation. Video cameras were used to record the horses while they were allowed to recover undisturbed. Video recordings were later viewed and recoveries were evaluated on a 100-point scale by three graders.ResultsHorses in illuminated and darkened recovery stalls were evaluated on total anesthesia time, minimum alveolar concentration hours of isoflurane, time to first movement, time to standing, and total recovery score. There were no significant differences between the two groups in any of the measured parameters.ConclusionRecovering horses in a darkened versus an illuminated recovery stall may provide no benefit.Clinical relevanceDarkening the recovery stalls for horses recovering from general anesthesia may be unnecessary.     

Serum biomarker profiling in cancer studies: a question of standardisation?

Companion animals are exposed to similar environmental conditions and carcinogens as humans. In some animal cancers, there also appears to be the same genetic changes associated as in humans. However, little work has been carried out in cancer biomarker identification in animals. The recent dramatic advances in molecular medicine, genomics, proteomics and translational research will allow biomarker identification, which may provide the best strategies for veterinarians and clinicians to combat disease by early diagnosis and administration of effective treatments. Proteomics may have important applications in cancer diagnosis, prognosis and predictive clinical outcome that could directly change clinical practice by affecting critical elemen‐ts of care and management. This review summarizes the advances in proteomics that has propelled us to this exciting age of clinical proteomics, and highlights the future work that is required for this to become a reality. In this review, we will discuss the available proteomic technologies and their limitations, and highlight the key areas of research and how they have been used to discover cancer biomarkers. The principles described here are equally applicable to human and animal disease, but implementation of ‘omic’ technologies requires stringent guidelines for collection of clinical material, the application of analytical techniques and interpretation of the data.